Revolution Medicines' daraxonrasib receives FDA Orphan Drug Designation for pancreatic cancer treatment, offering hope for patients with limited options in this deadly disease.
Revolution Medicines awarded FDA National Priority Voucher for daraxonrasib (RMC-6236), a breakthrough RAS inhibitor targeting pancreatic and lung cancer in Phase 3 trials.
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.
Stifel initiates Erasca coverage with Buy rating and $4 target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition.
Revolution Medicines' Daraxonrasib shows great promise for metastatic pancreatic cancer, targeting RAS mutations. It works well in both new and previously treated patients, alone or with chemo, with good safety. Big trials are planned to make it a new standard of care.
